Omeros (NASDAQ:OMER) Stock Price Crosses Above Two Hundred Day Moving Average of $3.00

Shares of Omeros Co. (NASDAQ:OMER) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.00 and traded as high as $3.82. Omeros shares last traded at $3.38, with a volume of 429,470 shares trading hands.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, April 3rd.

Omeros Stock Performance

The firm has a market cap of $195.84 million, a price-to-earnings ratio of -1.80 and a beta of 1.34. The business has a 50 day simple moving average of $3.90 and a 200-day simple moving average of $3.00.

Hedge Funds Weigh In On Omeros

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. lifted its position in shares of Omeros by 258.0% during the 2nd quarter. BlackRock Inc. now owns 4,154,952 shares of the biopharmaceutical company’s stock worth $22,603,000 after buying an additional 2,994,468 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Omeros by 2.3% during the 1st quarter. Vanguard Group Inc. now owns 3,434,697 shares of the biopharmaceutical company’s stock worth $20,642,000 after buying an additional 76,869 shares in the last quarter. Stifel Financial Corp lifted its position in shares of Omeros by 4.7% during the 2nd quarter. Stifel Financial Corp now owns 2,056,835 shares of the biopharmaceutical company’s stock worth $11,189,000 after buying an additional 93,215 shares in the last quarter. State Street Corp raised its holdings in shares of Omeros by 2.8% in the 1st quarter. State Street Corp now owns 1,412,609 shares of the biopharmaceutical company’s stock worth $8,490,000 after purchasing an additional 38,498 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Omeros by 98.4% in the 2nd quarter. Geode Capital Management LLC now owns 1,253,711 shares of the biopharmaceutical company’s stock worth $6,820,000 after purchasing an additional 621,819 shares during the period. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.